Nicole Lemerond - Dec 20, 2024 Form 4 Insider Report for InMed Pharmaceuticals Inc. (INM)

Role
Director
Signature
/s/ Eric A Adams, attorney-in-fact for Ms. Nicole Lemerond
Stock symbol
INM
Transactions as of
Dec 20, 2024
Transactions value $
$0
Form type
4
Date filed
12/23/2024, 09:25 AM
Previous filing
Aug 14, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INM Employee Stock Option (Right to Buy) Award $0 +550 +129.41% $0.00 975 Dec 20, 2024 Common shares 550 $4.14 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options were granted on 12/20/2024 and will vest 100% on the one-year anniversary of the grant date (December 19, 2025) or immediately prior to the next Annual General Meeting, whichever is sooner.
F2 On November 14, 2024, the common stock of InMed was reverse split on a 1-for-20 basis. This number reflects that reverse stock split.